How Target Therapy can Induce Cardiotoxicity: The Onco-Cardiologist Point of View
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2017, Vol 3, Issue 2
Abstract
The life expectancy of an oncological patient has been increased significantly decades due to the evolution of cancer therapies. The aim of this paper is to review how these new target molecules, which have a direct impact on the cancer cell as opposed to the classical chemotherapy, known to all of us for a long time. How do they act specifically? What are their cardiotoxic effects at a short and long time period? How can they be monitored? How can they be prevented and treated? And above all, how can we prevent an oncological patient to become a cardiovascular one later on, due to induced cardiotoxicity caused by oncological therapies. We have to treat our patients as a whole and not only, target therapy to one of the pieces of the puzzle.
Authors and Affiliations
Joana Espiga de Macedo
Keywords
Related Articles
- EP ID EP551922
- DOI 10.17140/CSMMOJ-3-119
- Views 148
- Downloads 0
A Case of Choroidal Metastasis from Small-Cell Lung Carcinoma
A 74-year-old man visited to our hospital due to severe visual disturbance in his left eye for recent one month. Fundoscopy demonstrated the serous retinal detachment at the nose side of the left eye (Figure 1A, arrows).
Application of Radionuclides and Antibody-Drug Conjugates to Target Cancer
Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilisation of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in...
Classifying Lung Adenocarcinoma and Squamous Cell Carcinoma using RNA-Seq Data
Background: Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are two primary subtypes of non-small cell lung carcinoma (NSCLC). Currently, the most widely used method to discriminate between LUAD and LU...
How Target Therapy can Induce Cardiotoxicity: The Onco-Cardiologist Point of View
The life expectancy of an oncological patient has been increased significantly decades due to the evolution of cancer therapies. The aim of this paper is to review how these new target molecules, which have a direct impa...
The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy
Early life exposure to a variety of insults during sensitive windows of development can reprogram normal physiological responses and alter disease susceptibility later in life. During this process, inflammation triggered...